- Previous Close
1,390.85 - Open
1,405.95 - Bid --
- Ask --
- Day's Range
1,386.90 - 1,435.55 - 52 Week Range
1,052.00 - 1,755.90 - Volume
162,220 - Avg. Volume
349,114 - Market Cap (intraday)
359.84B - Beta (5Y Monthly) 0.30
- PE Ratio (TTM)
49.18 - EPS (TTM)
28.79 - Earnings Date May 5, 2025 - May 9, 2025
- Forward Dividend & Yield 4.00 (0.29%)
- Ex-Dividend Date Nov 27, 2024
- 1y Target Est
1,645.75
Ipca Laboratories Limited, a pharmaceutical company, manufactures and markets formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India, Europe, Africa, the Americas, Asia, CIS, and Australasia. It offers APIs in therapeutic areas of anti-hypertensive, anti-malarial, diuretic, DMARD, and anthelmintic. The company also provides generic and branded formulations in the therapeutic segments, including allergy, anti-neoplastic/cancer drugs, anti-arthritic, anti-epileptic, anti-hypertensive, cardiology, diabetes, dermatology, diabetology, emollients/protectives, fever, gastroenterology, hematology, helminthics, hepatoprotectives, immunosuppressant, infectious diseases, malaria, neurology, neuropathic pain, and NSAIDs, as well as nutraceuticals, ophthalmology, oral anti diabetes drug, orthopedics, probiotics, psychiatry, respiratory, rheumatology, and urology. It also exports its products worldwide. The company was incorporated in 1949 and is based in Mumbai, India.
www.ipca.com17,335
Full Time Employees
March 31
Fiscal Year Ends
Sector
Recent News: IPCALAB.NS
View MorePerformance Overview: IPCALAB.NS
Trailing total returns as of 4/2/2025, which may include dividends or other distributions. Benchmark is S&P BSE SENSEX (^BSESN) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: IPCALAB.NS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: IPCALAB.NS
View MoreValuation Measures
Market Cap
353.46B
Enterprise Value
356.04B
Trailing P/E
48.39
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
4.08
Price/Book (mrq)
5.27
Enterprise Value/Revenue
4.12
Enterprise Value/EBITDA
22.72
Financial Highlights
Profitability and Income Statement
Profit Margin
8.36%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
87.27B
Net Income Avi to Common (ttm)
7.29B
Diluted EPS (ttm)
28.79
Balance Sheet and Cash Flow
Total Cash (mrq)
9.03B
Total Debt/Equity (mrq)
14.81%
Levered Free Cash Flow (ttm)
--